User profiles for "author:Brian Slomovitz"
Brian SlomovitzFlorida international university Verified email at msmc.com Cited by 10779 |
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
BM Slomovitz, TW Burke, PJ Eifel, LM Ramondetta… - Gynecologic …, 2003 - Elsevier
OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of
patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at …
patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at …
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer
BM Slomovitz, RL Coleman - Clinical Cancer Research, 2012 - AACR
Endometrial cancer is the most common gynecologic malignancy in the United States.
Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important …
Overactivation of the PI3K/AKT/mTOR pathway, a signaling pathway that plays an important …
Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases
Objectives. Synchronous primary cancers of the endometrium and ovary are found in 10% of
women with ovarian cancer and 5% of women with endometrial cancer. The purpose of this …
women with ovarian cancer and 5% of women with endometrial cancer. The purpose of this …
[HTML][HTML] Dostarlimab for primary advanced or recurrent endometrial cancer
MR Mirza, DM Chase, BM Slomovitz… - … England Journal of …, 2023 - Mass Medical Soc
Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …
death 1 receptor. The combination of chemotherapy and immunotherapy may have …
[HTML][HTML] Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
KM Schmeler, HT Lynch, L Chen… - … England Journal of …, 2006 - Mass Medical Soc
Background Women with the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime …
have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime …
Risk factors for young premenopausal women with endometrial cancer
PT Soliman, JC Oh, KM Schmeler, CC Sun… - Obstetrics & …, 2005 - journals.lww.com
OBJECTIVE: Endometrial cancer is the most common gynecologic malignancy in the United
States. The mean age at diagnosis is 61 years; however, 5–30% of women are aged …
States. The mean age at diagnosis is 61 years; however, 5–30% of women are aged …
Association between adiponectin, insulin resistance, and endometrial cancer
PT Soliman, D Wu, G Tortolero‐Luna, KM Schmeler… - Cancer, 2006 - Wiley Online Library
BACKGROUND Obesity is a well known risk factor for the development of endometrial
cancer; however, weight alone does not account for all cases. The authors hypothesized that …
cancer; however, weight alone does not account for all cases. The authors hypothesized that …
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma
BM Slomovitz, KH Lu, T Johnston, RL Coleman… - Cancer, 2010 - Wiley Online Library
BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene
that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA …
that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA …
[HTML][HTML] Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label …
Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high …
[HTML][HTML] Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma
BM Slomovitz, Y Jiang, MS Yates… - Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Purpose The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in
endometrial cancer (EC). Hormonal manipulation leads to response in some patients with …
endometrial cancer (EC). Hormonal manipulation leads to response in some patients with …